Neurology

FDA Approves First Vaccine for Dengue, With Restrictions

Dengvaxia is for the prevention of dengue disease caused by all dengue virus serotypes in people aged 9 to 16 years who have previously had laboratory-confirmed dengue infection and who live in endemic areas.
FDA Approvals

Source link




Related posts

Type 2 Diabetes Risk May Be Lower in Women With Migraine

Newsemia

IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease

Newsemia

Reader response: Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy